Ted Myles

Track

Insider profile

Currently holds a position at AMAG Pharmaceuticals Inc

Performance

Overall performance
3.9
Performance over holding periods
3.9
30 days 90 days 120 days
Average return 12% 8.2% 15.1%
Success rate 100% 68% 82%
Transactions
5 0% Buy
34 71% Buy
47 69% Buy
Ranking by holding-period performance

Positions

Position Company Period
Chief Financial Officer, Chief Operating Officer, Executive Vice President, Treasurer AMAG Pharmaceuticals Inc Jan. 9, 2020 -
Independent Director Scholar Rock Holding Corp Nov. 19, 2018 - May 29, 2020
Chief Financial Officer, Executive Vice President, Treasurer AMAG Pharmaceuticals Inc Dec. 31, 2017 - Jan. 9, 2020
Chief Financial Officer, Senior Vice President - Finance, Treasurer AMAG Pharmaceuticals Inc April 11, 2016 - Dec. 31, 2017
Chief Financial Officer, Chief Operating Officer Ocata Therapeutics Inc July 21, 2014 - Feb. 10, 2016
Interim President, Chief Financial Officer, Executive Vice President - Corporate Development Ocata Therapeutics Inc Jan. 22, 2014 - July 21, 2014
Chief Financial Officer, Executive Vice President - Corporate Development Ocata Therapeutics Inc June 12, 2013 - Jan. 22, 2014
Ted Myles's trades of Scholar Rock Holding Corp's stock


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date Company B/S Transaction type Nb. shares
Price
Value 		Number of shares Price Value Details
2025-06-05 2025-06-05
PrS Proposed sale
70,262
64.45
US$1,921,658 		70,262 64.45 US$1,921,658
2025-03-12 2025-03-10
PlS Planned sale
59,740 -7.5%
142.21
US$2,356,573 		59,740 -7.5% 142.21 US$2,356,573
2025-03-12 2025-03-10
PlS Planned sale
85,258 +24.7%
290.28
US$713,799 		85,258 +24.7% 290.28 US$713,799
2025-03-10 2025-03-10
PrS Proposed sale
161,890
35.00
US$5,666,150 		161,890 35.00 US$5,666,150
2025-02-20 2025-02-18
S Sale
7,809 -5.3%
36.83
US$287,598 		7,809 -5.3% 36.83 US$287,598
2025-01-21 2025-01-16
S Sale
12,539 -7.8%
44.20
US$554,189 		12,539 -7.8% 44.20 US$554,189
2024-10-10 2024-10-08
PlS Planned sale
37,187 -18.8%
34.90
US$1,297,659 		37,187 -18.8% 34.90 US$1,297,659
2024-10-07 2024-10-07
PrS Proposed sale
243,427
32.50
US$7,911,378 		243,427 32.50 US$7,911,378
2024-10-07 2024-10-07
PlS Planned sale
31,250 -16.2%
29.05
US$907,812 		31,250 -16.2% 29.05 US$907,812
2024-10-07 2024-10-07
PlS Planned sale
25,812 -11.8%
27.27
US$703,893 		25,812 -11.8% 27.27 US$703,893
2024-10-07 2024-10-07
PlS Planned sale
37,206 -14.6%
26.83
US$998,237 		37,206 -14.6% 26.83 US$998,237
2024-10-07 2024-10-07
PlS Planned sale
111,972 -30.5%
25.61
US$2,867,603 		111,972 -30.5% 25.61 US$2,867,603
2024-06-18 2024-06-17
S Sale
9,458 -4.5%
8.98
US$84,978 		9,458 -4.5% 8.98 US$84,978
2024-02-21 2024-02-16
S Sale
4,744 -2.2%
15.74
US$74,686 		4,744 -2.2% 15.74 US$74,686
2024-01-18 2024-01-16
S Sale
6,634 -3.9%
15.93
US$105,670 		6,634 -3.9% 15.93 US$105,670
2023-12-29 2023-12-29
PrS Proposed sale
12,459
20.32
US$253,167 		12,459 20.32 US$253,167
2023-12-29 2023-12-29
PlS Planned sale
300 -0.2%
19.51
US$5,853 		300 -0.2% 19.51 US$5,853
2023-12-29 2023-12-29
PlS Planned sale
12,159 -6.7%
18.82
US$228,780 		12,159 -6.7% 18.82 US$228,780
2023-12-08 2023-12-07
PlS Planned sale
24,914 -12.9%
17.53
US$436,820 		24,914 -12.9% 17.53 US$436,820
2023-12-07 2023-12-07
PrS Proposed sale
24,914
17.53
US$436,820 		24,914 17.53 US$436,820
2023-11-03 2023-11-02
PlS Planned sale
35,007 -17.2%
12.51
US$438,039 		35,007 -17.2% 12.51 US$438,039
2023-11-02 2023-11-02
PrS Proposed sale
35,007
12.30
US$430,586 		35,007 12.30 US$430,586
2021-11-15 2021-11-15
PlS Planned sale
4,879 -16.8%
35.05
US$171,006 		4,879 -16.8% 35.05 US$171,006
2021-11-15 2021-11-12
PlS Planned sale
49,848 -67.4%
35.12
US$1,750,437 		49,848 -67.4% 35.12 US$1,750,437
2021-11-15 2021-11-11
PlS Planned sale
23,574 -49.4%
35.20
US$829,857 		23,574 -49.4% 35.20 US$829,857